Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Gynecology

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 84 articles: HTML format

Single Articles

September 2025
1. KASPER E, Boulouard F, Basset N, Golmard L, et al
   Deciphering dual clinical entities associated with TP53 pathogenic variants: Insights from 53,085 HBOC panel analyses in French laboratories.
   Int J Cancer. 2025;157:897-907.
   PubMed     Abstract available
   
   
   July 2025
2. BOWDEN SJ, Bodinier B, Paraskevaidi M, Kalliala I, et al
   DNA methylation signatures of cervical pre-invasive and invasive disease: An epigenome-wide association study.
   Int J Cancer. 2025;157:305-316.
   PubMed     Abstract available
   
   
   
3. BJORGE T, Stoer NC, Hverven SK, Nygard M, et al
   Risk of high-grade cervical lesions in the second round of primary human papillomavirus testing in CervicalScreen Norway: A population-based cohort study.
   Int J Cancer. 2025;157:251-259.
   PubMed     Abstract available
   
   
   
4. BEIERLEIN M, Haberle L, Nabieva N, Maass N, et al
   Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial.
   Int J Cancer. 2025 Jul 11. doi: 10.1002/ijc.70037.
   PubMed     Abstract available
   
   
   
5. CHANDRAN A, Mackie A, Sasieni P, Arbyn M, et al
   Technical, legal and ethical framework of cancer audit in cervical screening - Summary of best practices for organised programmes delineated through an expert group consultation.
   Int J Cancer. 2025;157:32-40.
   PubMed     Abstract available
   
   
   June 2025
6. WEI SQ, Leduc V, Potter B, Paradis G, et al
   Preeclampsia and risk of breast cancer: A longitudinal cohort study of tumor histology.
   Int J Cancer. 2025 Jun 25. doi: 10.1002/ijc.70025.
   PubMed     Abstract available
   
   
   
7. ZHENG Y, Han J, Qu Y, Wang J, et al
   DNA methylation biomarkers for cervical cancer risk prediction in HIV-positive Nigerian women.
   Int J Cancer. 2025 Jun 9. doi: 10.1002/ijc.35502.
   PubMed     Abstract available
   
   
   
8. HEMMINGSEN CH, Kjaer SK, Hjorth S, Norby U, et al
   Maternal hormonal contraceptive use and childhood central nervous system tumor risk in a large Scandinavian cohort.
   Int J Cancer. 2025 Jun 5. doi: 10.1002/ijc.35509.
   PubMed     Abstract available
   
   
   May 2025
9. GAMA Q, Wang L, Wu P, Liu S, et al
   Effects of levonorgestrel-releasing intrauterine system on recurrence and fertility outcomes during assisted reproduction after complete remission of early endometrioid endometrial cancer and precancerous lesions: A retrospective cohort study.
   Int J Cancer. 2025 May 14. doi: 10.1002/ijc.35465.
   PubMed     Abstract available
   
   
   April 2025
10. KALJOUW S, Jansen EEL, Schevenhoven VJC, de Kok IMCM, et al
    Should the age range of the Dutch hrHPV-based cervical cancer screening program be broadened? A modelling study using cohort effects.
    Int J Cancer. 2025 Apr 28. doi: 10.1002/ijc.35435.
    PubMed     Abstract available
    
    
    
11. WEI Y, Gu L, Zhang Y, Yang Q, et al
    Efficacy of ALA-PDT in treating cervical low-grade squamous intraepithelial lesions with high-risk HPV patients: A multicentre randomized controlled trial.
    Int J Cancer. 2025 Apr 23. doi: 10.1002/ijc.35450.
    PubMed     Abstract available
    
    
    
12. WITJES VM, de Hullu JA, Hermkens DMA, Smolders YHCM, et al
    Nationwide implementation and evaluation of the Tumor-First workflow for genetic testing in ovarian carcinoma.
    Int J Cancer. 2025 Apr 16. doi: 10.1002/ijc.35440.
    PubMed     Abstract available
    
    
    
13. GE X, Feng Y, Tan S, Mao W, et al
    Gestational colorectal cancer: Mechanisms, treatments, and prognosis.
    Int J Cancer. 2025 Apr 3. doi: 10.1002/ijc.35425.
    PubMed     Abstract available
    
    
    
14. COOLEY V, Fortner RT, Mukama T, Naudin S, et al
    Prospective evaluation of 92 protein biomarkers for early detection of endometrial cancer.
    Int J Cancer. 2025 Apr 3. doi: 10.1002/ijc.35428.
    PubMed     Abstract available
    
    
    March 2025
15. ESLAHI M, Pizzato M, Heikkinen S, Martinsen JI, et al
    Socioeconomic position and risk of cervical cancer in the Nordic countries: Results from the Nordic Occupational Cancer Study.
    Int J Cancer. 2025 Mar 13. doi: 10.1002/ijc.35349.
    PubMed     Abstract available
    
    
    
16. LI Z, Liu P, Yin A, Zhang B, et al
    Global landscape of cervical cancer incidence and mortality in 2022 and predictions to 2030: The urgent need to address inequalities in cervical cancer.
    Int J Cancer. 2025 Mar 3. doi: 10.1002/ijc.35369.
    PubMed     Abstract available
    
    
    
17. WEI W, Zhang Y, Li Y, Huang J, et al
    Hypoxia-mediated high expression of TRIM15 promotes malignant progression of high-grade serous ovarian cancer through activation of AKT signaling pathway by K63 ubiquitination.
    Int J Cancer. 2025 Mar 3. doi: 10.1002/ijc.35387.
    PubMed     Abstract available
    
    
    
18. CHEN Q, Yao X, Quan J, Jia X, et al
    The variations in the natural history of high-risk human papillomavirus infections in Chinese healthy women aged 27-45 years compared with 18-26 years: A prospective cohort study.
    Int J Cancer. 2025;156:1043-1054.
    PubMed     Abstract available
    
    
    February 2025
19. HAUG AJ, Stoer N, Langseth H, Siafarikas F, et al
    Non-steroidal anti-inflammatory medication use and endometrial cancer survival: A population-based Norwegian cohort study.
    Int J Cancer. 2025 Feb 24. doi: 10.1002/ijc.35363.
    PubMed     Abstract available
    
    
    
20. NICHOLS HB, Anderson C, Baggett CD, Cannizzaro NT, et al
    Pregnancy and pregnancy outcomes after adolescent and young adult cancer in the AYA horizon study.
    Int J Cancer. 2025 Feb 24. doi: 10.1002/ijc.35383.
    PubMed     Abstract available
    
    
    
21. PEREMIQUEL-TRILLAS P, Martinez JM, Paytubi S, Frias-Gomez J, et al
    Acceptability and somatic mutations in cervicovaginal self-sampling for early endometrial cancer detection in women with Lynch syndrome.
    Int J Cancer. 2025 Feb 14. doi: 10.1002/ijc.35368.
    PubMed     Abstract available
    
    
    
22. KEBEDE HB, Mekuria S, Asegid N, Forslund O, et al
    High-risk human papillomavirus genotypes in previously unscreened reproductive-age women in Ethiopia: A community-based cohort study.
    Int J Cancer. 2025 Feb 14. doi: 10.1002/ijc.35335.
    PubMed     Abstract available
    
    
    
23. RUNELLO F, Jary A, Duin S, Kim Y, et al
    DNA methylation and copy number alterations in the progression of HPV-associated high-grade vulvar intraepithelial lesion.
    Int J Cancer. 2025 Feb 12. doi: 10.1002/ijc.35366.
    PubMed     Abstract available
    
    
    
24. HARPER DM, Paczos T, Ridder R, Huh WK, et al
    p16/ki-67 dual stain triage of individuals positive for HPV to detect cervical precancerous lesions.
    Int J Cancer. 2025 Feb 4. doi: 10.1002/ijc.35353.
    PubMed     Abstract available
    
    
    January 2025
25. LOFLING LL, Stoer NC, Sloan EK, Nafisi S, et al
    Beta-blockers and epithelial ovarian cancer survival: A Norwegian population-based cohort study.
    Int J Cancer. 2025 Jan 26. doi: 10.1002/ijc.35348.
    PubMed     Abstract available
    
    
    
26. DU L, Sun H, Tang L, Hao S, et al
    Cervical cancer incidence rates considering migration status in mainland China using Bayesian model-Estimation based on 2016 cancer registry data.
    Int J Cancer. 2025 Jan 23. doi: 10.1002/ijc.35346.
    PubMed     Abstract available
    
    
    
27. ARROYO MUHR LS, Wang J, Hassan SS, Yilmaz E, et al
    Nationwide registry-based trial of risk-stratified cervical screening.
    Int J Cancer. 2025;156:379-388.
    PubMed     Abstract available
    
    
    
28. LUND E, Busund LR, Holden L
    Curvilinear incidence models for parity in the entire fertility range for cancers of the breast, ovary, and endometrium: A follow-up of the Norwegian 1960 Census.
    Int J Cancer. 2025 Jan 3. doi: 10.1002/ijc.35312.
    PubMed     Abstract available
    
    
    December 2024
29. VERROU E, Koutoukoglou P, Kontana E, Gogolopoulos S, et al
    Incidence, characteristics and outcome of therapy-related myeloid neoplasms in women with epithelial ovarian cancer after exposure to poly-ADPribose polymerase inhibitors: A cancer center experience.
    Int J Cancer. 2024 Dec 17. doi: 10.1002/ijc.35299.
    PubMed     Abstract available
    
    
    
30. VERHOEF L, Bleeker MCG, Polman N, Kroon KR, et al
    Colposcopy referrals and CIN3 detection after triage by host cell DNA methylation and/or HPV genotyping in HPV positive women with low-grade cytology from a population-based Dutch primary HPV screening trial.
    Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35289.
    PubMed     Abstract available
    
    
    
31. HUNG FH, Peng HP, Hung CF, Hsieh LL, et al
    Performance evaluation of predictive models for detecting MMR gene mutations associated with Lynch syndrome in cancer patients in a Chinese cohort in Taiwan.
    Int J Cancer. 2024;155:2201-2210.
    PubMed     Abstract available
    
    
    
32. KEN-AMOAH S, Redl E, Domson BKS, Barrett JE, et al
    Performance of the WID-qEC test to detect uterine cancers in black women with abnormal uterine bleeding: A prospective observational cohort study in Ghana.
    Int J Cancer. 2024 Dec 10. doi: 10.1002/ijc.35260.
    PubMed     Abstract available
    
    
    
33. TUNG HJ, Wang YC, Lin CY, Liao MJ, et al
    Human papillomavirus prevalence, genotype distribution, and prognostic factors of vaginal cancer.
    Int J Cancer. 2024;155:1996-2008.
    PubMed     Abstract available
    
    
    November 2024
34. PEDERSEN BT, Sonne SB, Pedersen H, Andreasen EK, et al
    Participation and relative cost of attendance by direct-mail compared to opt-in invitation strategy for HPV self-sampling targeting cervical screening non-attenders: A large-scale, randomized, pragmatic study.
    Int J Cancer. 2024 Nov 23. doi: 10.1002/ijc.35263.
    PubMed     Abstract available
    
    
    
35. LIU H, Zou M, Shen M, Kamarulzaman A, et al
    HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: A cost-effectiveness analysis.
    Int J Cancer. 2024 Nov 17. doi: 10.1002/ijc.35242.
    PubMed     Abstract available
    
    
    
36. JENSEN A, Guleria S, Albieri V, Nohr B, et al
    Fertility treatment and risk of ovarian cancer in a large nationwide cohort of infertile Danish women.
    Int J Cancer. 2024 Nov 14. doi: 10.1002/ijc.35251.
    PubMed     Abstract available
    
    
    
37. BONAVENTURE A, Simpson J, Kane E, Roman E, et al
    Maternal illnesses during pregnancy and the risk of childhood cancer: A medical-record based analysis (UKCCS).
    Int J Cancer. 2024 Nov 13. doi: 10.1002/ijc.35166.
    PubMed     Abstract available
    
    
    
38. WATLING CZ, Kelly RK, Watts EL, Graubard BI, et al
    Total testosterone, sex hormone-binding globulin, and free testosterone concentrations and risk of primary liver cancer: A prospective analysis of 200,000 men and 180,000 postmenopausal women.
    Int J Cancer. 2024 Nov 5. doi: 10.1002/ijc.35244.
    PubMed     Abstract available
    
    
    
39. SCHAAFSMA M, Schuurman TN, Kootstra P, Issa D, et al
    Nationwide cohort study on the risk of high-grade cervical dysplasia and carcinoma after conservative treatment or hysterectomy for adenocarcinoma in situ.
    Int J Cancer. 2024 Nov 4. doi: 10.1002/ijc.35237.
    PubMed     Abstract available
    
    
    
40. SCHEI-ANDERSEN AJ, Hendricks LAJ, van der Post RS, Mensenkamp AR, et al
    Histopathological phenotyping of cancers in PTEN Hamartoma Tumor Syndrome for improved recognition: A single-center study.
    Int J Cancer. 2024;155:1567-1576.
    PubMed     Abstract available
    
    
    
41. LOUVANTO K, Verhoef L, Pimenoff V, Eriksson T, et al
    Low methylation marker levels among human papillomavirus-vaccinated women with cervical high-grade squamous intraepithelial lesions.
    Int J Cancer. 2024;155:1549-1557.
    PubMed     Abstract available
    
    
    October 2024
42. DESCAMPS P, Bosch Jose FX, Monsonego J, Neisingh O, et al
    Cervical cancer screening: Sharing best practices and addressing common challenges in cervical cancer screening programs.
    Int J Cancer. 2024 Oct 26. doi: 10.1002/ijc.35220.
    PubMed    
    
    
    
43. LEHTINEN M, Elfstrom M, Vanska S, Dillner J, et al
    Elimination of cervical cancer by refined vaccination and screening.
    Int J Cancer. 2024 Oct 25. doi: 10.1002/ijc.35228.
    PubMed    
    
    
    
44. KOKEMULLER L, Ramachandran D, Schurmann P, Geffers R, et al
    Germline variants of homology-directed repair or mismatch repair genes in cervical cancer.
    Int J Cancer. 2024 Oct 23. doi: 10.1002/ijc.35221.
    PubMed     Abstract available
    
    
    
45. BIGNOTTI E, Simeon V, Ardighieri L, Kuhn E, et al
    TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study.
    Int J Cancer. 2024 Oct 16. doi: 10.1002/ijc.35203.
    PubMed     Abstract available
    
    
    
46. MISHRA GA, Pimple SA, Anand KV, Kulkarni VY, et al
    Acceptability and validity of HPV self-sampling for cervical cancer screening among women living in different ecological settings in India.
    Int J Cancer. 2024 Oct 16. doi: 10.1002/ijc.35222.
    PubMed     Abstract available
    
    
    
47. ZHENG Y, Vdovichenko N, Schurmann P, Ramachandran D, et al
    Comparative sequencing study of mismatch repair and homology-directed repair genes in endometrial cancer and breast cancer patients from Kazakhstan.
    Int J Cancer. 2024 Oct 14. doi: 10.1002/ijc.35215.
    PubMed     Abstract available
    
    
    
48. CUI M, Song L, Mao R, Lyu Y, et al
    Exposure to polycyclic aromatic hydrocarbons promotes the progression of low-grade cervical intraepithelial neoplasia: A population-based cohort study in China.
    Int J Cancer. 2024;155:1162-1171.
    PubMed     Abstract available
    
    
    September 2024
49. CHEN J, Shi J, Cao Y, Li C, et al
    A new treatment approach of toripalimab in combination with concurrent platinum-based chemoradiotherapy for locally advanced cervical cancer: A phase II clinical trial.
    Int J Cancer. 2024 Sep 28. doi: 10.1002/ijc.35206.
    PubMed     Abstract available
    
    
    
50. JONSSON S, Jonsson H, Lundin E, Haggstrom C, et al
    Pelvic inflammatory disease and risk of borderline ovarian tumors: A national population-based case-control study in Sweden.
    Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35180.
    PubMed     Abstract available
    
    
    
51. DEBEAUDRAP P, Kabore FN, Setha L, Tegbe J, et al
    Performance of visual inspection, partial genotyping, and their combination for the triage of women living with HIV who are screen positive for human papillomavirus: Results from the AIMA-CC ANRS 12375 multicentric screening study.
    Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35190.
    PubMed     Abstract available
    
    
    
52. OSTRBENK VALENCAK A, Kroon KR, Fabjan D, Mlakar J, et al
    Clinically validated HPV assays offer comparable long-term safety in primary cervical cancer screening: A 9-year follow-up of a population-based screening cohort.
    Int J Cancer. 2024 Sep 24. doi: 10.1002/ijc.35200.
    PubMed     Abstract available
    
    
    
53. NA R, Jordan SJ, DeFazio A, Williams M, et al
    Use of menopausal hormone therapy before and after diagnosis and ovarian cancer survival-A prospective cohort study in Australia.
    Int J Cancer. 2024 Sep 2. doi: 10.1002/ijc.35154.
    PubMed     Abstract available
    
    
    
54. FUJITA M, Nagashima K, Shimazu M, Suzuki M, et al
    Effectiveness of self-sampling human papillomavirus test on precancer detection and screening uptake in Japan: The ACCESS randomized controlled trial.
    Int J Cancer. 2024;155:905-915.
    PubMed     Abstract available
    
    
    August 2024
55. VLEDDER A, Paijens ST, Loiero D, Maagdenberg A, et al
    B cells critical for outcome in high grade serous ovarian carcinoma.
    Int J Cancer. 2024 Aug 22. doi: 10.1002/ijc.35149.
    PubMed     Abstract available
    
    
    
56. SCHAAFSMA M, van den Helder R, Mom CH, Steenbergen RDM, et al
    Recurrent cervical cancer detection using DNA methylation markers in self-collected samples from home.
    Int J Cancer. 2024 Aug 22. doi: 10.1002/ijc.35143.
    PubMed     Abstract available
    
    
    July 2024
57. 
    Expression of Concern: miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6.
    Int J Cancer. 2024 Jul 31. doi: 10.1002/ijc.35121.
    PubMed    
    
    
    
58. KADERLY RASMUSSEN EL, Hannibal CG, Hertzum-Larsen R, Kjaer SK, et al
    Biopsy-verified vulvar lichen sclerosus and the risk of non-vulvar cancer: A nationwide cohort study.
    Int J Cancer. 2024 Jul 17. doi: 10.1002/ijc.35101.
    PubMed     Abstract available
    
    
    
59. LYNGE E, Bennekou Schroll J, Andersen B, Balasubramaniam K, et al
    Cervical cancer incidence in Denmark: Disentangling determinants of time trend.
    Int J Cancer. 2024 Jul 14. doi: 10.1002/ijc.35081.
    PubMed     Abstract available
    
    
    
60. MORO F, Ciancia M, Zace D, Vagni M, et al
    Role of artificial intelligence applied to ultrasound in gynecology oncology: A systematic review.
    Int J Cancer. 2024 Jul 11. doi: 10.1002/ijc.35092.
    PubMed     Abstract available
    
    
    
61. GILHAM C, Nedjai B, Scibior-Bentkowska D, Reuter C, et al
    Long-term prediction by DNA methylation of high-grade cervical intraepithelial neoplasia: Results of the ARTISTIC cohort.
    Int J Cancer. 2024;155:81-92.
    PubMed     Abstract available
    
    
    June 2024
62. 
    Correction to "Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer".
    Int J Cancer. 2024 Jun 21. doi: 10.1002/ijc.35059.
    PubMed    
    
    
    
63. ALHARBI M, Lai A, Godbole N, Guanzon D, et al
    Enhancing precision targeting of ovarian cancer tumor cells in vivo through extracellular vesicle engineering.
    Int J Cancer. 2024 Jun 7. doi: 10.1002/ijc.35055.
    PubMed     Abstract available
    
    
    May 2024
64. LOBIN C, Orang'o EO, Were E, Muthoka K, et al
    Cost-effectiveness analysis of alternative screening strategies for the detection of cervical cancer among women in rural areas of Western Kenya.
    Int J Cancer. 2024 May 27. doi: 10.1002/ijc.35036.
    PubMed     Abstract available
    
    
    
65. CHAO X, Kai Z, Wu H, Wang J, et al
    Fragmentomics features of ovarian cancer.
    Int J Cancer. 2024 May 20. doi: 10.1002/ijc.34981.
    PubMed     Abstract available
    
    
    
66. HANSEN BT, Nygard M, Castle PE, Burger EA, et al
    Sociodemographic characteristics associated with cervical cancer screening participation by send-to-all and opt-in HPV self-sampling: Who benefits? Results from a randomized controlled trial among long-term non-attending women in Norway.
    Int J Cancer. 2024 May 15. doi: 10.1002/ijc.34989.
    PubMed     Abstract available
    
    
    
67. ILLAH O, Scott M, Redl E, Barrett JE, et al
    High performance of the DNA methylation-based WID-qEC test for detecting uterine cancers independent of sampling modalities.
    Int J Cancer. 2024 May 13. doi: 10.1002/ijc.35000.
    PubMed     Abstract available
    
    
    
68. ROSTAMI S, Rounge TB, Pestarino L, Lyle R, et al
    Differential levels of circulating RNAs prior to endometrial cancer diagnosis.
    Int J Cancer. 2024 May 11. doi: 10.1002/ijc.34951.
    PubMed     Abstract available
    
    
    
69. HUANG C, Bu H, Wang Y, Chu R, et al
    Association between coffee and tea consumption and ovarian cancer incidence: A prospective analysis in the PLCO dataset.
    Int J Cancer. 2024 May 11. doi: 10.1002/ijc.34982.
    PubMed     Abstract available
    
    
    
70. TAGUCHI A, Kato K, Furusawa A, Hara K, et al
    Heterogeneous treatment effect of dose-dense paclitaxel plus carboplatin therapy for advanced ovarian cancer.
    Int J Cancer. 2024 May 7. doi: 10.1002/ijc.34996.
    PubMed     Abstract available
    
    
    
71. FROMHAGE G, Obermayr E, Bednarz-Knoll N, Van Gorp T, et al
    Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortium.
    Int J Cancer. 2024 May 6. doi: 10.1002/ijc.34976.
    PubMed     Abstract available
    
    
    
72. KITAHARA CM, Surcel HM, Falk R, Pfeiffer RM, et al
    Early-pregnancy sex steroid and thyroid function hormones, thyroid autoimmunity, and maternal papillary thyroid cancer incidence in the Finnish Maternity Cohort.
    Int J Cancer. 2024 May 2. doi: 10.1002/ijc.34974.
    PubMed     Abstract available
    
    
    April 2024
73. OBERMAYR E, Mohr T, Schuster E, Braicu EI, et al
    Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium.
    Int J Cancer. 2024 Apr 27. doi: 10.1002/ijc.34978.
    PubMed     Abstract available
    
    
    
74. BUDUKH A, Dora T, Sancheti S, Singh V, et al
    Outcome of early detection approach in control of breast, cervical, and oral cancer: Experience from a rural cancer center in India.
    Int J Cancer. 2024 Apr 20. doi: 10.1002/ijc.34966.
    PubMed     Abstract available
    
    
    
75. DOWNHAM L, Rol ML, Forestier M, Romero P, et al
    Field experience with the 8-HPV-type oncoprotein test for cervical cancer screening among HPV-positive women living with and without HIV in LMICs.
    Int J Cancer. 2024 Apr 11. doi: 10.1002/ijc.34953.
    PubMed     Abstract available
    
    
    
76. SINGINI MG, Muchengeti M, Sitas F, Chen WC, et al
    Antibodies against high-risk human papillomavirus proteins as markers for noncervical HPV-related cancers in a Black South African population, according to HIV status.
    Int J Cancer. 2024 Apr 5. doi: 10.1002/ijc.34919.
    PubMed     Abstract available
    
    
    March 2024
77. DUUS AH, Hannibal CG, Baandrup L, Zheng G, et al
    Prediagnostic use of menopausal hormone therapy and long-term survival of localized epithelial ovarian cancer: The Extreme study.
    Int J Cancer. 2024 Mar 26. doi: 10.1002/ijc.34936.
    PubMed     Abstract available
    
    
    
78. BAANDRUP L, Hannibal CG, Hertzum-Larsen R, Kjaer SK, et al
    Biopsy-verified vulvar lichen sclerosus: Incidence trends 1997-2022 and increased risk of vulvar squamous precancer and squamous cell carcinoma.
    Int J Cancer. 2024 Mar 22. doi: 10.1002/ijc.34927.
    PubMed     Abstract available
    
    
    
79. LI N, Yi H, Sun W, Sundquist J, et al
    Revealing genes associated with cervical cancer in distinct immune cells: A comprehensive Mendelian randomization analysis.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34911.
    PubMed     Abstract available
    
    
    
80. HOLY P, Hlavac V, Seborova K, Susova S, et al
    Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34908.
    PubMed     Abstract available
    
    
    
81. STERPETTI AV, Gabriele R, Iannone I, Sapienza P, et al
    Reduced adherence to cervical cancer screening. The importance of information and education for women with low education and low-income.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34907.
    PubMed    
    
    
    
82. OLTHOF EMG, Aitken CA, Siebers AG, van Kemenade FJ, et al
    The impact of loss to follow-up in the Dutch organised HPV-based cervical cancer screening programme.
    Int J Cancer. 2024 Mar 4. doi: 10.1002/ijc.34902.
    PubMed     Abstract available
    
    
    February 2024
83. LINDQUIST S, Frederiksen K, Petersen LK, Kjaer SK, et al
    The risk of vaginal, vulvar and anal precancer and cancer according to high-risk HPV status in cervical cytology samples.
    Int J Cancer. 2024 Feb 28. doi: 10.1002/ijc.34896.
    PubMed     Abstract available
    
    
    
84. WEN TM, Xu XQ, Zhao XL, Pan CH, et al
    Efficacy and immunogenicity of AS04-HPV-16/18 vaccine in females with existing cervical HR-HPV infection at first vaccination: A pooled analysis of four large clinical trials worldwide.
    Int J Cancer. 2024 Feb 17. doi: 10.1002/ijc.34882.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.